Cleantech Firm Expands Breakthrough Wound Solution to Veterans

Important Disclosures:

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc. and Clyra Medical Technologies.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

1. Disclosure for the quote from the John Newell article published on March 11, 2026

1. For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
2. Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a  U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Cleantech and life sciences company BioLargo Inc. (BLGO:OTCQX) announced that its subsidiary Clyra Medical Technologies has entered an exclusive agreement with Spartan Medical Inc. to resell its FDA-cleared ViaCLYR™ advanced wound irrigation solution to government healthcare facilities worldwide, according to a September 3 release. The company said the agreement establishes a dedicated commercial channel serving U.S. government healthcare facilities.

"This third reseller agreement for Clyra's ViaClyr opens a direct path for federal government purchasing and distribution," BioLargo Chief Executive Officer Dennis Calvert said in the release. "Together with its existing U.S. distributor Advanced Solution LLC, and an international distribution agreement with Al Hikma covering 18 countries, Spartan Medical's government healthcare channel strengthens Clyra's commercial rollout and supports revenue growth as it scales manufacturing ahead of the anticipated national launch of its surgical product next year."

The agreement brings Clyra's Clyrasept™ Copper-Iodine Complex Solution (CICS) to healthcare facilities where wound care remains a key clinical concern, according to the release.

ViaCLYR, powered by Clyrasept, is "the first-ever, broad-spectrum antimicrobial optimized for speed, efficacy, persistence, and biocompatibility," the company said. In clinical tests cited in the release, ViaCLYR killed 99.9999% of 18 pathogens within one minute of application and is "proven effective against MRSA, VRE, and Candida auris," the company said. ViaCLYR provides persistent 72-hour antimicrobial management without reapplication and, because it is non-cytotoxic, does not require rinsing, the release said. By comparison, the company said, standard wound care solutions have fast kill times but persist for 60 seconds or less and require regular, repeated reapplication and wound dressing changes. The performance figures reflect company-reported testing; ViaCLYR's FDA 510(k) clearance covers cleansing, irrigating, and debriding wounds, not an antimicrobial efficacy determination.

"Our groundbreaking technology was developed to address the four critical dimensions of wound care and infection control without compromise or tradeoffs," said Clyra Chief Executive Officer Steve Harrison. "We are proud to partner with the Spartan team to bring better care to those who have bravely and proudly served our country. We are confident that ViaCLYR will quickly become the standard of care across the VA, military, and government healthcare continuum."

Clyra's ViaCLYR Added to Defense Logistics Agency Catalog

ViaCLYR is FDA 510(k)-cleared for cleansing, irrigating, and debriding a wide range of wound types, including first- and second-degree burns, Stage I-IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds, and abrasions, as well as for moistening and lubricating absorbent wound dressings, the release noted.

"Adding ViaCLYR to our product portfolio brings a game-changing solution to a persistent challenge faced by every facility we serve," said Vince Proffitt, president of Spartan Medical. "By offering parity pricing for a clearly superior product, Clyra is demonstrating a commitment to improving the care and long-term well-being of countless veterans, service members, and individuals treated in our government healthcare facilities."

ViaCLYR has now been added to the Defense Logistics Agency Electronic Catalog (ECAT) and is available for resale to Government healthcare facilities, including VA/DoD-operated or -managed facilities, Federal Bureau of Prisons facilities, Indian Health Service facilities, and other federal agency healthcare facilities, as well as certain civilian hospitals operating under VA Community Care/VA-funded contracts, Clyra said in the release.

Spartan Medical is a veteran-owned and operated government contractor serving the U.S. Department of Veterans Affairs, the U.S. Department of Defense, and other local, state, and federal agencies. Its senior executives bring leadership experience from both public and private-sector organizations, while the company focuses on addressing complex challenges through creative thinking, innovative solutions, and flexible, highly skilled teams.

Spartan Medical provides medical facilities with comprehensive solutions designed to improve patient care and outcomes, with a particular focus on U.S. military and veteran communities, the release said.

BioLargo Advances Its Businesses Toward Commercial Scale

BioLargo is advancing several business platforms toward commercialization, led by Clyra. ViaCLYR landed its first U.S. distributor order in February 2026 and an 18-country distribution deal with Dubai's Al-Hikma FZCO in May, while it booked US$154,000 in first-half revenue. Its next product, the surgical-irrigation solution Bioclynse, is slated to launch through a national distribution counterparty — extending the technology toward surgical use.

On the consumer side, the newly formed BioLargo CPG LLC plans an October relaunch of CupriDyne®-based household products, this time with BioLargo owning the brand and controlling the chain end to end, after the Pooph, Inc. license was revoked in September 2025. Its ONM Environmental unit keeps selling CupriDyne Clean and the equipment used to deploy it to municipalities, landfills, and industrial customers, supported by recurring Southern California contracts.

BioLargo Engineering, Science & Technologies (BLEST) generated US$1.888 million in first-half revenue — including roughly US$100,000 a month from U.S. Air Force air-quality work — and was awarded a US$1.2 million contract in April to design a pilot-scale minerals processing facility for the remediation and beneficial reuse of a legacy mineral-waste deposit in the western U.S.

In water treatment, BioLargo's Aqueous Electrostatic Concentrator has run at Lake Stockholm, New Jersey, for more than six months (10,000-plus hours), removing PFAS to state and federal limits while undergoing EPA and state testing. And BioLargo Energy Technologies is developing Cellinity, a long-duration liquid-sodium battery built on abundant domestic materials with a projected 20-plus-year life — now in customer and financing talks, but with no formal project financing agreements or factory development contracts and no revenue yet.

"We have important milestones that we expect to accomplish over the next six to nine months," Calvert said last month. "If those things happen, the thesis is working. If any of them do not, we will say so plainly and tell you why."

BioLargo will hold its stockholder town hall on September 10 at 1 p.m. Pacific (4 p.m. Eastern), where management plans to review second-quarter results and commercialization across its medical, water-treatment, odor-control, energy-storage, and engineering businesses.

Expert: Portfolio Covers Multiple Cleantech Markets

¹Technical Analyst John Newell of John Newell & Associates examined BioLargo's healthcare business through its Clyra Medical Technologies subsidiary in a March 11 report for Streetwise Reports. Newell said BioLargo has followed a measured commercialization strategy, first putting its proprietary technologies through rigorous scientific testing before leveraging established partners to broaden its market presence. He pointed to the company's diverse portfolio, which includes water treatment, environmental remediation, air-quality technologies, energy storage, and medical applications.

Newell identified Clyra as one of BioLargo's key healthcare assets, citing its copper-iodine technology, which has an antimicrobial component that functions as a preservative in the solution without causing cytotoxic effects. Newell also highlighted ViaCLYR's FDA 510(k) clearance, which allows the product to enter established medical-device distribution channels, while noting that the underlying platform is backed by approximately 40 issued and pending patents covering liquid, powder, hydrogel, and antimicrobial dressing products.

Citing the potential across BioLargo's technology portfolio, Newell assigned the company a Speculative Buy rating. He said BioLargo's disciplined approach to commercialization, combined with its focus on strategic partnerships, could position the company to capitalize on rising demand for advanced healthcare technologies and sustainable energy-storage solutions.

Oak Ridge Financial Analyst Richard Ryan characterized BioLargo's business strategy in a May 18 report as a "hub and spoke format invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan retained his Buy rating, saying the company's independent operating subsidiaries help distribute commercialization risk while enabling BioLargo to maintain substantial ownership interests in businesses targeting several rapidly growing markets.

The Catalyst: A Growing Wound Care Market Lifts Demand

The global wound care market is expected to expand from US$22.22 billion in 2025 to US$30.48 billion by 2030, representing a 6.5% CAGR, according to MarketsandMarkets. The research firm cited rising rates of chronic illnesses, an increase in traumatic wounds and burns, and greater healthcare needs among older populations as key drivers. With healthcare providers, insurers, and manufacturers focused on improving outcomes while reducing long-term costs, wound care is taking on greater importance across hospitals, outpatient centers, home healthcare, and long-term care facilities.

MarketsandMarkets also anticipates stronger demand for wound care products as providers manage growing numbers of chronic wounds, diabetic foot ulcers, pressure injuries, venous leg ulcers, surgical wounds, and trauma-related injuries. The report said delayed healing can drive up hospital costs, require more healthcare resources, and increase readmission rates, making effective wound management both a clinical necessity and a key tool for healthcare organizations seeking greater cost control and efficiency.

The timing lines up with a wound-cleansing market that is expanding steadily. In its Antimicrobial Wound Cleanser Market report, Towards Healthcare valued the segment at US$560.21 million in 2025 and US$585.42 million in 2026, projecting growth to US$869.99 million by 2035, a compound annual rate of 4.5% over the period.

The firm tied that growth to the same clinical problems Clyra's products target. "The globally accelerating burden of surgical procedures, burns, and road accidents is propelling demand for advanced wound cleanser solutions," Towards Healthcare wrote, pointing as well to a heightened focus on reducing hospital-acquired and surgical-site infections. Rising rates of diabetes and obesity, it added, are driving more non-healing wounds that require advanced cleansing, with diabetic foot ulcers, pressure injuries, and venous leg ulcers expected to fuel the fastest-growing part of the market.

The report also underscores where such products are used: hospitals account for roughly 52% of the market, and acute wounds account for about 62%, the setting Clyra is targeting through its listing on the Defense Logistics Agency catalog and distribution to government and VA/DoD healthcare facilities. Clyra's next product, the surgical-irrigation solution Bioclynse, extends the same technology toward the surgical-site infection risk the report flags as a core demand driver.

Ownership and Share Structure²

About 13.73% of BioLargo is owned by insiders and management. About 0.04% is held by institutions with 13F-disclosed institutional holdings only. The rest is retail.

Its market cap is US$31.23 million, with about 328.73 million shares outstanding. It trades in a 52-week range of US$0.08 and US$0.23.

Common Investor Questions

What did BioLargo and Clyra announce? Clyra Medical Technologies, a subsidiary of BioLargo, entered an exclusive agreement with Spartan Medical to resell its FDA-cleared ViaCLYR advanced wound-irrigation solution to U.S. government healthcare facilities worldwide. ViaCLYR has also been added to the Defense Logistics Agency's Electronic Catalog (ECAT).

What is ViaCLYR cleared to do? ViaCLYR is FDA 510(k)-cleared for cleansing, irrigating, and debriding a range of wound types, including first- and second-degree burns, Stage I-IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds and abrasions, and for moistening and lubricating absorbent dressings. That clearance covers the cleansing and irrigation function. The antimicrobial performance the company cites, such as killing 99.9999% of 18 pathogens in one minute and 72-hour persistence, comes from company-reported testing, not from an FDA efficacy determination, and its Clyrasept copper-iodine component is characterized as functioning as a preservative in the solution.

Why does the Spartan Medical deal matter? It gives Clyra an exclusive channel into federal healthcare buyers. Through the ECAT listing, ViaCLYR can be resold to VA/DoD facilities, Federal Bureau of Prisons and Indian Health Service facilities, other federal agency healthcare sites, and certain civilian hospitals under VA Community Care contracts. Spartan, a veteran-owned government contractor, is offering it at parity pricing.

How does this fit Clyra's broader rollout? Spartan is Clyra's third reseller arrangement, alongside U.S. distributor Advanced Solutions and an 18-country international agreement with Dubai's Al-Hikma FZCO. Clyra booked US$154,000 in first-half revenue and is scaling manufacturing ahead of the anticipated national launch of its surgical-irrigation product, Bioclynse, next year.